Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded...

Full description

Bibliographic Details
Main Authors: Timothy Vreeland, Diane Hale, Mark Faries, George E Peoples, Xianzhong Yu, Patrick McCarthy, Jessica Cindass, John Hyngstrom, James Jakub, Montaser F Shaheen, Guy Travis Clifton, Elizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, Anne E O’Shea, Robert Connor Chick, Franklin A Valdera, Ankur Tiwari, Phillip Kemp Bohan, Annelies Hickerson, Todd Smolinsky, Katryna Thomas, Adam C Berger, Jeffrey J Sussman, Thomas E Wagner
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e006665.full

Internet

https://jitc.bmj.com/content/11/8/e006665.full

Similar Items